IL6 and leukemia: Baicalein treatment significantly inhibited leukemia via attenuating vascular endothelial cell loss, edema, inflammatory cell infiltration, and blood clots, as well as reducing the serum levels of TNF-α, interleukin 1β (IL-1β), interleukin 6 (IL-6), and intercellular cell adhesion molecule-1 (ICAM-1).